查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1858269

肺炎治疗市场依治疗方法、给药途径、通路、病患年龄层、病原体类型和适应症类型划分－2025-2032年全球预测

Pneumonia Therapeutics Market by Therapy Type, Route Of Administration, Distribution Channel, Patient Age Group, Pathogen Type, Indication Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，肺炎治疗市场规模将成长至 338 亿美元，复合年增长率为 9.26%。

主要市场统计数据
基准年 2024 166.4亿美元
预计年份：2025年 181.9亿美元
预测年份：2032年 338亿美元
复合年增长率 (%) 9.26%

为所有相关人员提供一份全面的策略性介绍，阐述正在重新定义肺炎治疗的临床、监管和商业性趋势。

本导言透过对当代临床发展趋势、不断变化的法规环境以及正在重新定义相关利益者优先事项的不断演进的医疗服务模式进行综合分析，阐明了肺炎治疗的现状。该分析阐述了影响研究挑战、产品开发策略和患者管理管道的关键驱动因素，同时重点强调了科学创新与医疗保健系统需求之间的交集。

辨识科学创新、医疗服务模式和报销机制的变革性转变，这些转变正在加速肺炎治疗开发平臺的改变。

科学、医疗服务和资金筹措等各领域的变革正在汇聚，为肺炎治疗开闢新的创新途径。生技药品和免疫调节技术的进步拓展了传统抗感染药物以外的治疗选择，而对病原体和宿主反应的深入研究则推动了更具针对性的研发策略。同时，医疗服务正日益分散化。门诊管理、居家氧气疗法和远距监测正在减轻住院负担，并改变治疗方法的选择和实施方式。

分析2025年美国对肺炎治疗药物加征关税的累积经济影响、供应链影响及临床可近性影响。

2025年美国关税调整的累积影响将对肺炎治疗药物的供应链、筹资策略和临床取得管道产生多方面的影响。进口原料、呼吸设备组件或成品药的关税上调可能导致全球供应链分散的製造商生产成本上升、利润率下降。这种压力通常会导致製造商采取成本缓解措施，例如供应商多元化、关键组件近岸生产以及重新谈判供应商合同，以维持生产的连续性和产品的可负担性。

关键细分洞察揭示了治疗方法类型、给药途径、分销管道、患者人口统计特征、病原体谱和适应症类别如何相互作用

一个精细化的细分框架，能够识别不同治疗方法类型、给药途径、分销管道、患者群体特征、病原体类型和适应症方面的治疗方法差异化和商业性机会。治疗方法类型包括辅助性治疗（如皮质类固醇和雾化器）；抗感染药物（包括抗生素、抗真菌药物和抗病毒药物，其中抗生素又细分为Aminoglycosides、β-内酰胺类、大环内酯类、奎诺酮和四环霉素）；生技药品（包括免疫调节剂和单克隆抗体）；以及支持性治疗（专注于液体管理、人工呼吸器和氧气疗法）。这些区分至关重要，因为作用机制、安全性以及所需的临床环境决定了治疗方法在从急性护理到门诊护理的连续过程中所处的位置。

深入剖析美洲、欧洲、中东和非洲以及亚太地区如何影响临床实践、治疗途径和创新重点。

区域趋势正显着影响着美洲、欧洲、中东和非洲以及亚太地区的临床实践模式、医疗服务取得以及创新疗法的推广顺序。在美洲，医疗保健系统和支付方生态系统强调临床疗效和成本效益的证据，鼓励治疗方法已证实且具有显着经济提案的疗法。此外，某些市场的过渡期照护模式和门诊服务正在加速吸入和口服药物的推广应用，从而实现更早出院和居家照护。

公司层面的关键洞察，概述了领先的肺炎治疗药物开发商的策略定位、产品线差异化、合作以及商业化策略。

企业层面的发展趋势正日益凸显，其关注点不再局限于单一产品的上市，而是转向产品线差异化、策略伙伴关係和商业敏捷性。将标靶抗感染计画与互补生物疗法结合的研发企业，正致力于满足多样化的临床需求，同时开闢多条验证产品价值的途径。许可协议和合作开发伙伴关係正被广泛用于加速获取互补技术，例如快速诊断和吸入给药伙伴关係，这些技术能够强化临床管道并缩短产品上市时间。

行业领导者优化肺炎治疗临床开发、供应弹性、报销谈判和患者获取的实用策略

业界领导者必须推动一系列切实可行、影响深远的倡议，以在确保药品和医疗器材可及性和可负担性的同时，维持创新活力。首先，将卫生经济学终点和真实世界证据收集纳入试验设计，使临床开发项目与支付方的证据要求保持一致，将有助于促进报销谈判，并加速不同医疗机构的采用。其次，透过供应商多元化、区域製造能力和策略性库存管理来增强供应链韧性，将降低贸易中断和物流延误对药品和医疗设备供应的影响。

透明的调查方法，描述了肺炎治疗领域评估中使用的资料来源、检验方法、相关利益者访谈和分析框架。

本研究采用多方面方法，结合与关键相关利益者的直接对话、二手文献的综合分析以及迭代检验，以确保获得可靠的实践见解。资料来源包括已发表的临床文献、监管指导文件、医疗设备和治疗技术简报、各医疗系统的采购政策以及揭示企业策略行动的公开文件。透过对临床医生、医院采购负责人、生命週期管理专家和商业领域领导者的结构化访谈收集关键信息，以提供关于营运挑战和应用驱动因素的具体背景。

为参与肺炎治疗研发和推广的相关人员提供策略要务、风险缓解策略和机会管道的综合分析。

结论将分析结果提炼为策略要务，以指导各组织在肺炎治疗领域寻求以病人为中心的可持续解决方案。对标靶治疗和支持性护理的投资必须与务实的营运策略相结合，以确保在供应链和贸易逆境下患者能够获得治疗。同时，获得强有力的指南来证明其临床和经济价值，对于在各种医疗机构中实现广泛应用至关重要。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 一种用于治疗多重抗药性肺炎的新型吸入式抗生素的出现
  • 监管部门核准扩大血清型覆盖范围，加速儿童肺炎疫苗的上市速度
  • 在医院获得性肺炎的治疗中，生物标记指导的抗菌药物管理通讯协定的应用日益增多。
  • 针对抗抗生素肺炎链球菌菌株的噬菌体疗法研究投资激增
  • 将人工智慧诊断技术应用于重症肺炎病例的早期检测与分类
  • 针对重症肺炎患者发炎路径的单株抗体疗法研发管线不断扩大

第六章美国关税的累积影响，2025年

第七章 人工智慧的累积影响，2025年

第八章 肺炎治疗市场：依治疗方法划分

  • 辅助性治疗
    • 皮质类固醇
    • 喷雾器
  • 抗感染药物
    • 抗生素
      • Aminoglycosides
      • β-内酰胺类
      • 大环内酯类
      • 奎诺酮抗生素
      • 四环霉素
    • 抗真菌药物
    • 抗病毒药物
  • 生技药品
    • 免疫调节剂
    • 单株抗体
  • 支持性护理
    • 点滴管理
    • 人工呼吸呼吸系统护理
    • 氧气疗法

9. 按给药途径分類的肺炎治疗市场

  • 吸入
  • 静脉注射
  • 口服

第十章 按分销管道分類的肺炎治疗市场

  • 医院药房
  • 网路药房
  • 零售药房

第十一章 依患者年龄组别分類的肺炎治疗市场

  • 成人
  • 老年人
  • 儿童

第十二章 依病原体类型分類的肺炎治疗市场

  • 非典型肺炎
    • 衣原体
    • 退伍军人菌
    • 霉浆菌
  • 细菌
  • 真菌
  • 病毒性的

第十三章 依适应症类型分類的肺炎治疗市场

  • 社区型肺炎
  • 院内肺炎
  • 人工呼吸器相关

第十四章 各地区肺炎治疗市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 依组别分類的肺炎治疗市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 各国肺炎治疗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Pfizer Inc.
    • GlaxoSmithKline plc
    • Merck & Co., Inc.
    • Sanofi SA
    • Johnson & Johnson
    • Novartis AG
    • AstraZeneca plc
    • Bayer AG
    • Teva Pharmaceutical Industries Ltd.
    • Dr. Reddy's Laboratories Ltd.
Product Code: MRR-8E22B61932B6

The Pneumonia Therapeutics Market is projected to grow by USD 33.80 billion at a CAGR of 9.26% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 16.64 billion
Estimated Year [2025] USD 18.19 billion
Forecast Year [2032] USD 33.80 billion
CAGR (%) 9.26%

Comprehensive strategic introduction to the evolving clinical, regulatory, and commercial dynamics that are redefining pneumonia therapeutics for stakeholders

The introduction establishes the current state of pneumonia therapeutics through a synthesis of contemporary clinical developments, regulatory shifts, and evolving delivery models that are redefining stakeholder priorities. This narrative frames the principal drivers shaping research agendas, product development strategies, and patient management pathways while emphasizing the intersection of scientific innovation and healthcare system needs.

By situating therapeutic advances alongside changing care environments, this opening analysis clarifies how new mechanisms of action, adjunctive care approaches, and supportive technologies are influencing clinical decision making. It also highlights the crucial role of cross-functional collaboration among clinicians, payers, manufacturers, and supply chain partners in converting scientific promise into improved patient outcomes. Transitioning from a descriptive baseline, the introduction sets up subsequent sections to explore structural shifts, regulatory and trade pressures, segmentation nuances, regional dynamics, and strategic responses that will determine near-term trajectories for pneumonia therapeutics.

Identification of transformative shifts in scientific innovation, care delivery models, and reimbursement landscapes that are accelerating change across pneumonia therapeutic pipelines

Transformative shifts across science, care delivery, and financing are converging to create new pathways for innovation in pneumonia therapeutics. Advances in biologics and immune modulation are expanding therapeutic options beyond traditional anti-infectives, while the precision characterization of pathogens and host responses is driving more targeted development strategies. At the same time, care delivery is decentralizing: outpatient management, home oxygen and remote monitoring reduce inpatient burden and change how therapies are chosen and delivered.

Concurrently, payer and reimbursement models increasingly reward clinical outcomes and value-based approaches, which pressures developers to demonstrate differentiated benefits beyond pathogen clearance. Digital health tools and real-world evidence are being integrated into regulatory and reimbursement dialogues, accelerating adaptive trial designs and post-approval evidence generation. As a result, scientific innovation, care model evolution, and financing mechanisms are collectively reshaping prioritization across discovery, clinical development, and commercialization, requiring integrated strategies that balance efficacy, access, and economic sustainability.

Analysis of the cumulative economic, supply chain, and clinical access implications stemming from United States tariff actions in 2025 for pneumonia therapeutics

The cumulative effects of tariff adjustments enacted by the United States in 2025 create a multi-dimensional impact on pneumonia therapeutic supply chains, procurement strategies, and clinical access pathways. Increased duties on imported raw materials, components for respiratory devices, or finished pharmaceuticals can raise production costs and compress margins for manufacturers whose supply chains are globally distributed. This pressure often prompts cost mitigation responses such as supplier diversification, nearshoring of critical components, and renegotiation of supplier contracts to preserve manufacturing continuity and product affordability.

Beyond direct cost effects, tariffs can alter logistics and lead times for critical inputs such as APIs, single-use device components, and specialized medical equipment used in oxygen therapy and mechanical ventilation. These disruptions have downstream clinical implications when hospitals and procurement teams encounter variability in availability or elevated pricing that affects formulary decisions and stocking policies. Moreover, tariff-driven changes incentivize stronger supplier qualification processes, increased inventory buffers, and strategic stockpiling for critical items. In parallel, payers and health systems may intensify scrutiny of total cost of care, accelerating shifts toward therapeutics and delivery models that demonstrate durable clinical and economic value. In aggregate, the 2025 tariff dynamics pressure manufacturers to redesign supply networks and strengthen commercial arguments for value and access while health systems adapt procurement strategies to maintain clinical readiness.

Critical segmentation insights revealing how therapy types, administration routes, distribution channels, patient age cohorts, pathogen profiles, and indication categories interact

A nuanced segmentation framework illuminates where therapeutic differentiation and commercial opportunity intersect across therapy type, administration route, distribution channel, patient age group, pathogen type, and indication. Therapy type spans adjunctive therapies that include corticosteroids and device-based nebulizers, anti-infectives composed of antibiotics, antifungals, and antivirals with antibiotics further detailed into aminoglycosides, beta lactams, macrolides, quinolones, and tetracyclines, biologics that encompass immune modulators and monoclonal antibodies, and supportive therapies oriented around fluid management, mechanical ventilation, and oxygen therapy. These distinctions matter because mechanism of action, safety profiles, and required clinical settings determine where a therapy sits along the acute care to outpatient continuum.

Route of administration-covering inhalation, intravenous, and oral delivery-directly affects adherence, ease of outpatient management, and the complexity of supply logistics. Distribution channels ranging from hospital pharmacy to online and retail pharmacy shape go-to-market approaches, pricing strategies, and patient access pathways. Patient age groups, including adult, geriatric, and pediatric cohorts, demand tailored safety and dosing strategies and influence trial design and labeling priorities. Pathogen type segmentation, which includes atypical organisms subdivided into Chlamydophila, Legionella, and Mycoplasma, as well as bacterial, fungal, and viral causes, drives diagnostic requirements and targeted therapeutic development. Finally, indication type such as community acquired, hospital acquired, and ventilator associated pneumonia creates distinct clinical management algorithms, differing regulatory expectations, and variable pathways to adoption. Collectively, this segmentation matrix provides a roadmap for aligning R&D focus, clinical trial populations, and commercialization plans with unmet needs and operational realities.

In-depth regional insights on how Americas, Europe Middle East and Africa, and Asia-Pacific are each shaping clinical practice, access pathways, and innovation priorities

Regional dynamics exert a strong influence on clinical practice patterns, access to therapeutics, and the sequencing of innovation adoption across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, health systems and payer ecosystems emphasize evidence of clinical benefit and cost-efficiency, which incentivizes therapeutics with demonstrable outcomes and robust economic value propositions. Transitional care models and outpatient capabilities in certain markets also accelerate adoption of inhaled and oral regimens that facilitate earlier discharge and home-based care.

Europe, Middle East & Africa present heterogenous regulatory and reimbursement landscapes where centralized guidelines coexist with national-level variations in uptake and procurement. This mosaic drives the need for flexible regulatory strategies, regionally tailored clinical evidence packages, and differentiated pricing approaches. Asia-Pacific encompasses a spectrum from highly sophisticated healthcare markets to rapidly developing systems where access, local manufacturing capacity, and public health priorities shape adoption. Across these regions, differences in pathogen prevalence, diagnostic infrastructure, and hospital capacity influence the relative demand for biologics, targeted anti-infectives, and supportive technologies. Taken together, these regional characteristics require companies to deploy tailored regulatory engagement, supply planning, and evidence generation strategies that align with local clinical practices and procurement frameworks.

Key company-level insights outlining strategic positioning, pipeline differentiation, collaborative ventures, and commercialization strategies across leading pneumonia therapeutics developers

Company-level dynamics are increasingly defined by a focus on pipeline differentiation, strategic partnerships, and commercialization agility rather than singular product launches. Developers that combine targeted anti-infective programs with adjunctive biologic approaches position themselves to address heterogeneous clinical needs while creating multiple levers for value demonstration. Licensing agreements and co-development partnerships are commonly used to accelerate access to complementary technologies, such as rapid diagnostics or inhalation delivery platforms, that strengthen clinical adoption pathways and improve time-to-market execution.

At the commercial interface, companies are investing in evidence generation beyond pivotal trials, emphasizing real-world data collection, health economics and outcomes research, and post-authorization safety monitoring to meet payer and clinician expectations. Manufacturing strategies are evolving to incorporate dual-sourcing and regional production capacity for critical inputs and devices to mitigate supply interruptions. Finally, corporate strategies increasingly reflect a blend of selective M&A to secure complementary capabilities, targeted geographic expansion to capture access opportunities, and flexible commercial models that support hospital procurement teams and community providers in diverse settings.

Actionable strategic recommendations for industry leaders to optimize clinical development, supply resilience, reimbursement engagement, and patient access for pneumonia care

Industry leaders must pursue a set of pragmatic, high-impact actions to sustain innovation while safeguarding access and affordability. First, aligning clinical development programs with payer evidence requirements by embedding health economic endpoints and real-world evidence collection into trial designs will facilitate reimbursement discussions and accelerate uptake in diverse healthcare settings. Second, strengthening supply chain resilience through supplier diversification, regional manufacturing capacity, and strategic inventory management will reduce vulnerability to trade disruptions and logistic delays that affect both drug and device availability.

Third, companies should cultivate integrated partnerships with diagnostics providers and care delivery organizations to enable precision targeting of therapies and to support outpatient and home-based care models. Fourth, commercial strategies must balance tiered pricing and contracting flexibility with transparent value communication to hospitals, payers, and pharmacy channels. Fifth, embedding digital tools for adherence support, remote monitoring, and patient engagement can improve outcomes and create measurable value for health systems. By implementing these coordinated actions, organizations can simultaneously advance clinical innovation, reinforce access pathways, and create defensible commercial positions in a fragmented and rapidly evolving therapeutic landscape.

Transparent research methodology explaining data sources, validation approaches, stakeholder interviews, and analytical frameworks employed in assessing pneumonia therapeutic areas

This research employed a multi-method approach combining primary stakeholder engagement, secondary literature synthesis, and iterative validation to ensure robust, actionable insights. Data sources included published clinical literature, regulatory guidance documents, device and therapeutic technical briefs, procurement policies from diverse health systems, and public filings that illuminate strategic company behavior. Primary inputs were gathered through structured interviews with clinicians, hospital procurement specialists, lifecycle management experts, and commercial leaders who provided contextual detail on operational challenges and adoption drivers.

Analytical frameworks integrated qualitative thematic analysis with scenario mapping to identify risk factors and opportunity pathways across clinical, supply chain, and reimbursement dimensions. A validation layer reconciled conflicting signals by triangulating interview findings with documented regulatory precedents and technical specifications of devices and drug classes. Throughout the process, emphasis was placed on transparency in assumptions, traceability of evidence, and the reproducibility of key conclusions, ensuring that recommendations are grounded in observable practice and validated stakeholder perspectives.

A concluding synthesis that distills strategic imperatives, risk mitigations, and opportunity pathways for stakeholders engaged in pneumonia therapeutic development and delivery

The conclusion synthesizes the analysis into a set of strategic imperatives that guide organizations toward durable, patient-centered solutions in pneumonia therapeutics. Investment in targeted therapeutics and supportive care modalities must be paired with pragmatic operational strategies that preserve access amid supply chain and trade headwinds. Simultaneously, robust evidence generation that demonstrates clinical and economic value will be decisive in achieving broad adoption across varied care settings.

Risk mitigation requires proactive supply chain redesign, stronger partnerships across diagnostics and care delivery, and adaptable commercial approaches that respect regional heterogeneity. Opportunity lies in integrating diagnostics-driven therapeutics, expanding outpatient care capabilities, and leveraging digital health to enhance adherence and monitoring. Collectively, these imperatives form a coherent agenda for stakeholders seeking to advance therapeutic innovation while ensuring that clinical gains translate into measurable improvements in patient outcomes and health system performance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emergence of novel inhalable antibiotic formulations for multidrug resistant pneumonia treatment
  • 5.2. Regulatory approvals accelerating availability of pediatric pneumonia vaccines with expanded serotype coverage
  • 5.3. Rising adoption of biomarker-guided antibiotic stewardship protocols in hospital acquired pneumonia management
  • 5.4. Investment surge in phage therapy research targeting antibiotic resistant Streptococcus pneumoniae strains
  • 5.5. Integration of artificial intelligence diagnostics for early detection and classification of severe pneumonia cases
  • 5.6. Growing pipeline of monoclonal antibody therapies targeting inflammatory pathways in severe pneumonia patients

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Pneumonia Therapeutics Market, by Therapy Type

  • 8.1. Adjunctive Therapies
    • 8.1.1. Corticosteroids
    • 8.1.2. Nebulizers
  • 8.2. Anti Infectives
    • 8.2.1. Antibiotics
      • 8.2.1.1. Aminoglycosides
      • 8.2.1.2. Beta Lactams
      • 8.2.1.3. Macrolides
      • 8.2.1.4. Quinolones
      • 8.2.1.5. Tetracyclines
    • 8.2.2. Antifungals
    • 8.2.3. Antivirals
  • 8.3. Biologics
    • 8.3.1. Immune Modulators
    • 8.3.2. Monoclonal Antibodies
  • 8.4. Supportive Therapies
    • 8.4.1. Fluid Management
    • 8.4.2. Mechanical Ventilation
    • 8.4.3. Oxygen Therapy

9. Pneumonia Therapeutics Market, by Route Of Administration

  • 9.1. Inhalation
  • 9.2. Intravenous
  • 9.3. Oral

10. Pneumonia Therapeutics Market, by Distribution Channel

  • 10.1. Hospital Pharmacy
  • 10.2. Online Pharmacy
  • 10.3. Retail Pharmacy

11. Pneumonia Therapeutics Market, by Patient Age Group

  • 11.1. Adult
  • 11.2. Geriatric
  • 11.3. Pediatric

12. Pneumonia Therapeutics Market, by Pathogen Type

  • 12.1. Atypical
    • 12.1.1. Chlamydophila
    • 12.1.2. Legionella
    • 12.1.3. Mycoplasma
  • 12.2. Bacterial
  • 12.3. Fungal
  • 12.4. Viral

13. Pneumonia Therapeutics Market, by Indication Type

  • 13.1. Community Acquired
  • 13.2. Hospital Acquired
  • 13.3. Ventilator Associated

14. Pneumonia Therapeutics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Pneumonia Therapeutics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Pneumonia Therapeutics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Pfizer Inc.
    • 17.3.2. GlaxoSmithKline plc
    • 17.3.3. Merck & Co., Inc.
    • 17.3.4. Sanofi S.A.
    • 17.3.5. Johnson & Johnson
    • 17.3.6. Novartis AG
    • 17.3.7. AstraZeneca plc
    • 17.3.8. Bayer AG
    • 17.3.9. Teva Pharmaceutical Industries Ltd.
    • 17.3.10. Dr. Reddy's Laboratories Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. PNEUMONIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. PNEUMONIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PNEUMONIA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BETA LACTAMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BETA LACTAMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BETA LACTAMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BETA LACTAMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BETA LACTAMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BETA LACTAMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MACROLIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MACROLIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MACROLIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY QUINOLONES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY QUINOLONES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY QUINOLONES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY QUINOLONES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY QUINOLONES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY QUINOLONES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY IMMUNE MODULATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY IMMUNE MODULATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY IMMUNE MODULATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY IMMUNE MODULATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY IMMUNE MODULATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY IMMUNE MODULATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY FLUID MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY FLUID MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY FLUID MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY FLUID MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY FLUID MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY FLUID MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MECHANICAL VENTILATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MECHANICAL VENTILATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MECHANICAL VENTILATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MECHANICAL VENTILATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MECHANICAL VENTILATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MECHANICAL VENTILATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY OXYGEN THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY OXYGEN THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY OXYGEN THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY OXYGEN THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY OXYGEN THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY OXYGEN THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INHALATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INHALATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY CHLAMYDOPHILA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY CHLAMYDOPHILA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY CHLAMYDOPHILA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY CHLAMYDOPHILA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY CHLAMYDOPHILA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY CHLAMYDOPHILA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY LEGIONELLA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY LEGIONELLA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY LEGIONELLA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY LEGIONELLA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY LEGIONELLA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY LEGIONELLA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MYCOPLASMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MYCOPLASMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MYCOPLASMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MYCOPLASMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MYCOPLASMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MYCOPLASMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BACTERIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BACTERIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BACTERIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY FUNGAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY FUNGAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY FUNGAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY FUNGAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY FUNGAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY FUNGAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY VIRAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY VIRAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY VIRAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY VIRAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY VIRAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY VIRAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY COMMUNITY ACQUIRED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY COMMUNITY ACQUIRED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY COMMUNITY ACQUIRED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY COMMUNITY ACQUIRED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY COMMUNITY ACQUIRED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY COMMUNITY ACQUIRED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY HOSPITAL ACQUIRED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY HOSPITAL ACQUIRED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY HOSPITAL ACQUIRED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY HOSPITAL ACQUIRED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY HOSPITAL ACQUIRED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY HOSPITAL ACQUIRED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY VENTILATOR ASSOCIATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY VENTILATOR ASSOCIATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY VENTILATOR ASSOCIATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY VENTILATOR ASSOCIATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY VENTILATOR ASSOCIATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY VENTILATOR ASSOCIATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 286. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 287. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 290. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2024 (USD MILLION)
  • TABLE 292. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2025-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 294. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 296. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 298. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 299. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 300. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 301. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 302. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 303. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 304. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 305. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 306. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2025-2032 (USD MILLION)
  • TABLE 307. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2024 (USD MILLION)
  • TABLE 308. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2025-2032 (USD MILLION)
  • TABLE 309. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 310. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 311. LATIN AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 312. LATIN AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 313. LATIN AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 314. LATIN AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 315. LATIN